<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Indolent and smoldering systemic mastocytosis: Management and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Indolent and smoldering systemic mastocytosis: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Indolent and smoldering systemic mastocytosis: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cem Akin, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarbjit Saini, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3881112632"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Systemic mastocytosis (SM) consists of a group of disorders exhibiting excessive mast cell accumulation, typically in bone marrow and other extracutaneous tissues. Five variant forms have been delineated  (<a class="graphic graphic_table graphicRef82828" href="/z/d/graphic/82828.html" rel="external">table 1</a>). The five variants may be broadly divided into two groups, which differ in clinical presentation, treatment, and prognosis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM)</strong> – ISM and SSM usually have a clinically indolent course, with median survival measured in decades. Previously, SSM was described as a subcategory of ISM, but the 2017 World Health Organization classification of hematolymphoid neoplasms redefined SSM as a distinct subtype of SM [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced systemic mastocytosis</strong>, which has a more aggressive course with median survival measured in months to years and includes the following disease variants:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive systemic mastocytosis (ASM)</p><p class="bulletIndent2"><span class="glyph">•</span>Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)</p><p class="bulletIndent2"><span class="glyph">•</span>Mast cell leukemia (MCL)</p><p></p><p>The management and prognosis of ISM and SSM are similar and are discussed in this topic review. The management and prognosis of ASM, SM-AHN, and MCL are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis"</a>.)</p><p>The clinical manifestations, evaluation, and diagnosis of SM are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/103174.html" rel="external">"Systemic mastocytosis: Determining the subtype of disease"</a>.)</p><p></p><p>Issues related to children with cutaneous or systemic mastocytosis are also covered separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/103161.html" rel="external">"Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4785.html" rel="external">"Cutaneous mastocytosis: Treatment, monitoring, and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H605157198"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>ISM accounts for more than 70 percent of all SM cases in the published literature, while SSM is rare. In both variants, patients may or may not have the characteristic skin lesions of maculopapular cutaneous mastocytosis (MPCM; formerly called urticaria pigmentosa)  (<a class="graphic graphic_picture graphicRef63025" href="/z/d/graphic/63025.html" rel="external">picture 1</a>). Patients may suffer a variety of episodic symptoms, including flushing, dyspepsia, and/or diarrhea, or they may experience recurrent anaphylaxis or persistent bone pain, neuropsychiatric symptoms, and fatigue. Morbidity in ISM and SSM is most commonly related to mast cell mediator release and anaphylaxis. Therefore, treatment of the clinically indolent SM subtypes is focused on preventing mast cell activation and minimizing the resulting symptoms when it does occur [<a href="#rid2">2</a>]. In one study, severe anaphylaxis was seen more in patients with ISM compared with those with more aggressive forms of disease (aggressive systemic mastocytosis [ASM], SM with an associated hematologic neoplasm [SM-AHN], and mast cell leukemia [MCL]) [<a href="#rid3">3</a>]. (See <a class="local">'Access to epinephrine'</a> below.)</p><p>In addition to the morbidity associated with mast cell mediator release, there is some risk of progression to more severe forms of mastocytosis. ISM carries a low risk of progression, while the risk with SSM is intermediate. (See <a class="local">'Monitoring for progression'</a> below.)</p><p class="headingAnchor" id="H526537312"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>Patients with any form of SM may experience episodic symptoms of mast cell activation, including apparent allergic-like reactions triggered by a variety of exposures. Anaphylaxis is more common in ISM and SSM compared with advanced forms of the disease.</p><p class="headingAnchor" id="H2685235147"><span class="h2">Elevated risk of anaphylaxis</span><span class="headingEndMark"> — </span>Up to one-half of adult patients with mastocytosis experience anaphylaxis [<a href="#rid4">4-7</a>]. Symptoms of anaphylaxis in mastocytosis frequently involve hypotension, syncope or presyncope associated with flushing, tachycardia, and gastrointestinal cramping, while urticaria and angioedema are less common. One study found atopy, lack of skin lesions of maculopapular cutaneous mastocytosis (MPCM), higher total immunoglobulin E (IgE), and lower baseline tryptase levels (27 versus 42 ng/mL) to be risk factors for anaphylaxis in mastocytosis [<a href="#rid8">8</a>]. Another study similarly found lack of MPCM but, in contrast, higher tryptase levels (60 versus 21 ng/mL) in patients who experience anaphylaxis [<a href="#rid5">5</a>]. All patients with SM should be educated about anaphylaxis and about triggers for mast cell degranulation and how to avoid them. They should consider wearing a medical identification bracelet, especially if they have already experienced anaphylaxis. In addition, patients can be equipped with an anaphylaxis emergency action plan or wallet card that identifies the condition and describes the proper treatment of anaphylaxis. Action plan forms are available in English and Spanish from Food Allergy Research and Education (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.foodallergy.org%252Fliving-food-allergies%252Ffood-allergy-essentials%252Ffood-allergy-anaphylaxis-emergency-care-plan%26data%3D04%7C01%7CMichael.Bottari%2540wolterskluwer.com%7C69e354c9a85b41457a2d08d8d9befae3%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637498761558925481%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3DRDdSv%252BmwjS2IGMJSEEUVZILHzhl4hXgju4PM8DCUzwU%253D%26reserved%3D0&amp;token=t282DwPDIBfsLs5gDG5p%2FcW0IJ1rA3BFgttAxHPnEIr4kjp%2BZKfQqzsTItL7UzEKQOcJe%2BDDLiIYoAbuGc4BL3puRARj12teLH9qoiF0RoHuyrVNoay6MPSBmhTrYPiRafjpeb%2BfC5I%2FewfUaJtgHJMj8XZSE64TuvdAZIoPvqtBbtFODqPpoH3Cwz5HWoHq7%2BcTgMmn5gYlXpRUWvE%2FBRaLoj3%2B54qskJKOAkPY5VpMz1FoYZja%2FCZStv%2FB1QE4zmNS7IqLC6CsMnVMNqkaGnujmBg2uDKzoiGKT78fAb9sFU9h35J16JONhIkDmtHrpgsX1azly45Lsv7JK9NjokZOZ9PMXiytoc1beG6ggIBGfUtQcy8JamSyRSjlKWy9%2FDexDj31Dpx7%2BNAjcEUfgMjzJZqpOGARiGU%2B3gICn9JEx7Jl3B3sk5wPMRP4WlusV0sQ04ExcMg3WJS28jJ7YaDrcwc759XDwzVtRlJLtb4oULk03YDmAr4pNZacfPwo&amp;TOPIC_ID=118890" target="_blank">Food Allergy &amp; Anaphylaxis Emergency Care Plan</a>) and the American Academy of Pediatrics (Allergy and Anaphylaxis Emergency Plan <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.aap.org%252Fen-us%252FDocuments%252FAAP_Allergy_and_Anaphylaxis_Emergency_Plan.pdf%26data%3D04%7C01%7CMichael.Bottari%2540wolterskluwer.com%7C69e354c9a85b41457a2d08d8d9befae3%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637498761558935434%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3DHh4x2Tg0RXTKuewzO%252BZpSw6TpC5Oma%252BMfoXGb8sTVuk%253D%26reserved%3D0&amp;token=N2qdDpAdBrGIdjO%2Bsh7qdz%2FZEUV2Ug98owpHM%2BdhCSJSyU8Lh6dDyCiKmQlrweKhKKi10F4fvgf9kkn2PDHuNjUTFMTEtYNHWhkd7Z7dru9gxMCXzUSGag%2BVqpOUXnNKv2vHI%2FneEoFCrWiyt8Rjw%2Fd8pZqbwWTQDSU2bzMGF%2BDSlwRx%2BZ0L8od0HKkVWyjSLwYWtjD7Mj4%2B%2FVmvjulhA5k5M7%2FjrDcHsALlnBOQvapr%2FbRnVqUCbvr7rfworeVCJNooIQu3iuIYaTqAKpNoj6eVj3SvPv8VwP3I56JPUZLh4JX1LBQ%2FX7OG1PA2Ywo7MW9rIFsu1GlWodvXqw0qpRgUFX4GCLJV9gtyLcEDRXTEWdbRAWGhkJaCXjyGG8rI8RTMbUnVcBzqDV2KwwfGyTz8IJDicFfHIIP09zxYg%2FHHu85wibw9IR3lQgT7ZAFmcFiJG3Cc7dtG7IKiM7AidLTirXtYzbg4J7Kuh4toalg%3D&amp;TOPIC_ID=118890" target="_blank">English</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fdownloads.aap.org%252FAAP%252FPDF%252FAAEP.Spanish.PDF.rm.1.26.21.pdf%26data%3D04%7C01%7CMichael.Bottari%2540wolterskluwer.com%7C69e354c9a85b41457a2d08d8d9befae3%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637498761558935434%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C1000%26sdata%3DwgRDRWY1vYMou9UclxHFboaU1iOzsJnUHmMeu7P3i5E%253D%26reserved%3D0&amp;token=s%2FqKNX5dznFbQOE2C4yHLc2iOE47EzLf08uhoPS5wn9B4SREj0U%2FUKar99opEhhvxlsYFMBDHqP0t0Zej6sqR5a7fYK8tPOCsemEFiPMxO1wAbuAtq3uBqTVMD4l%2B517JK7T5rBevgIvpdKEEZWBKTxZv%2FN%2BivZEBMTxla746LphhIGmbS2AVSaYXWuG6Sny3w1G3TwHDL3diN0kSGcf8JYveZ7lm9RGr03DXD2dFQNvnQ1%2FNF%2B%2FDUTF60SQ3QQccg39mxDzJENyCqnadKW09DuvY%2FCr3rOSUcBzsBxWQNvJHP3qDM2jvMYuUgc48bdvupAldFmKocUEO0v1DWsaXV4i6AgNKLDCX85XwvlK%2FgEktJKvnBuzRsxq6bCAT3JomGD%2BcquMXpdvekapPMWTGWMP1aQ8YI3hf3nbJRNwQnxodLHbPkGEe0pK%2BYLQGcoasldDdc%2BmL8NozpeoeuFFPg%3D%3D&amp;TOPIC_ID=118890" target="_blank">Spanish</a>). These plans are appropriate for patients with anaphylaxis from any cause.</p><p class="headingAnchor" id="H1962836320"><span class="h3">Access to epinephrine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> is the primary medical treatment for anaphylaxis, and patients should have at least two doses of epinephrine in a self-injectable form available at all times since a single dose may be inadequate to counteract the massive release of mediators that can occur [<a href="#rid9">9</a>]. They should also be taught to lie flat if they experience lightheadedness or presyncope during symptomatic episodes because hypotension is a prominent feature of anaphylaxis in this population. Guidance in prescribing epinephrine autoinjectors is provided separately. (See  <a class="medical medical_review" href="/z/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment"</a>.)</p><p class="headingAnchor" id="H3482713323"><span class="h3">Obtaining tryptase measurements after episodes of symptoms</span><span class="headingEndMark"> — </span>If patients experience episodes of symptoms that resemble anaphylaxis, serum tryptase should be obtained (ideally between 15 minutes and 3 hours after the onset of symptoms). A form requesting that tryptase be drawn can be given to patients to pass along to emergency care clinicians  (<a class="graphic graphic_form graphicRef109873" href="/z/d/graphic/109873.html" rel="external">form 1</a>).</p><p>Elevations in serum tryptase can help determine, retrospectively, if the events were truly caused by mast cell mediator release. However, because the results are not immediately available, the information is not useful in acute diagnosis. If serum tryptase increases ≥2 ng/mL + 1.2 x baseline in the hours following signs/symptoms, then those signs/symptoms can be attributed to mast cell activation.</p><p class="headingAnchor" id="H3095661430"><span class="h3">Trigger avoidance</span><span class="headingEndMark"> — </span>Patients with SM should be aware of the different triggers that can provoke mediator release from mast cells (eg, medications, medical procedures, and dietary factors). Of note, patients vary considerably in their sensitivity to specific triggers, so not all triggers are relevant to a given individual, and patients only need to avoid those exposures that have caused symptoms.</p><p>Possible triggers include:</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to either heat and humidity or to cold</p><p class="bulletIndent1"><span class="glyph">●</span>Acute emotional stress</p><p class="bulletIndent1"><span class="glyph">●</span>Very strenuous exercise</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol and spicy foods</p><p class="bulletIndent1"><span class="glyph">●</span>Infections, fever</p><p class="bulletIndent1"><span class="glyph">●</span>Anesthesia, surgery, and endoscopic procedures</p><p></p><p class="headingAnchor" id="H353316272"><span class="h4">Problematic medications</span><span class="headingEndMark"> — </span>Medications that can trigger mast cell activation may include <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and other nonsteroidal antiinflammatory drugs (NSAIDs), opioids, antibiotics (most commonly <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>), radiocontrast agents, and certain muscle relaxers used during anesthesia. Alternative medications that are usually tolerated are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4785.html" rel="external">"Cutaneous mastocytosis: Treatment, monitoring, and prognosis", section on 'Problematic medications'</a> and  <a class="medical medical_review" href="/z/d/html/4785.html" rel="external">"Cutaneous mastocytosis: Treatment, monitoring, and prognosis", section on 'Medications that are usually tolerated'</a>.)</p><p class="headingAnchor" id="H66853075"><span class="h4">Insect stings</span><span class="headingEndMark"> — </span>Stings from wasps, honey bees, fire ants, and other Hymenoptera can precipitate anaphylaxis in patients with mastocytosis, especially in those who have also developed IgE-mediated sensitization. Any patient with SM and systemic symptoms in response to a Hymenoptera sting should be tested for venom allergy, and those testing positive should be treated with venom immunotherapy (VIT) to reduce the risk of anaphylaxis upon subsequent stings. Patients with negative skin and in vitro venom-specific IgE should be retested in six months. (See  <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis", section on 'Information for patients'</a> and  <a class="medical medical_review" href="/z/d/html/4090.html" rel="external">"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action"</a>.)</p><p class="headingAnchor" id="H4063882598"><span class="h4">Preparation for medical, surgical, and radiologic procedures</span><span class="headingEndMark"> — </span>If patients have had procedures or surgery since developing a mast cell disorder, we attempt to retrieve the medical records of that procedure. If the patient had trouble tolerating the intervention, the medical records can help guide the selection of different perioperative drugs, and, if the procedure was tolerated, the same medications could be used again.</p><p>We routinely administer premedications prior to surgery (especially those that require general anesthesia), minor medical procedures, or the administration of radiocontrast dyes. Retrospective data support this approach [<a href="#rid10">10-13</a>].</p><p>Local and regional anesthesia are safer alternatives than general anesthesia. Local anesthetics are generally well tolerated. The optimal regimen for prevention of mast cell degranulation in mastocytosis patients has not been formally studied.</p><p>We administer the following one hour before the procedure, although the efficacy of this approach has not been studied (adult dosing):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">Diphenhydramine</a>, 25 to 50 mg orally or intravenously (IV) or equivalent doses of another oral antihistamine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">Famotidine</a>, 20 mg orally or IV (or another H2 antihistamine).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a> (optional), 10 mg orally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> (optional; preferred if the patient has frequent or hypotensive episodes of mast cell activation or has had problems tolerating anesthesia or surgery in the past), 25 to 50 mg orally, 12 hours and 1 to 2 hours prior to procedure.</p><p></p><p>The anesthesiologist and surgeon involved should be aware of the patient's susceptibility to anaphylaxis during and for several hours after the procedure and be prepared to treat it promptly and obtain a serum tryptase level. Physical triggers during procedures may include extremes of temperature, friction, and pressure. In addition, if the patient's tolerance of NSAIDs is unknown, these agents, especially in injectable forms (eg, <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">ketorolac</a>), should be avoided as severe reactions can result.</p><p>After the procedure, the patient can resume normal daily medications. A few patients will have increased symptoms for several days, so we generally ensure that they are taking at least a combination of H1 and H2 antihistamines daily until fully recovered if that was not part of their medication regimen.</p><p class="headingAnchor" id="H1772820273"><span class="h3">Vaccinations (including COVID-19 vaccines)</span><span class="headingEndMark"> — </span>Most adults with mastocytosis tolerate routine vaccinations without difficulty. Several studies have documented the tolerance of most patients of all ages to vaccination, including vaccination to prevent coronavirus disease 2019 (COVID-19) [<a href="#rid14">14-20</a>].</p><p>Vaccination against COVID-19 is recommended, although patients with mastocytosis who are experiencing severe or uncontrolled symptoms of mast cell mediator release at the time that vaccination is offered should first be treated until the symptoms are controlled before receiving the vaccine. In addition, patients with a history of anaphylaxis should be observed for 30 to 60 minutes after vaccination [<a href="#rid14">14</a>]. An international consensus panel suggested that patients with mast cell disorders receiving COVID-19 vaccines be premedicated with H1 antihistamines 30 to 60 minutes before vaccination [<a href="#rid14">14</a>]. Glucocorticoids, H2 antihistamines, and <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, which are sometimes given to these patients prior to other vaccinations, should be given only if felt to be critical as the effect on the immune response to messenger ribonucleic acid (mRNA) vaccines is unstudied.</p><p class="headingAnchor" id="H3208906725"><span class="h2">Pregnancy and delivery</span><span class="headingEndMark"> — </span>SM does not appear to reduce fertility, and patients with ISM can have healthy pregnancies, although symptoms may worsen during gestation [<a href="#rid21">21</a>]. Mastocytosis is not genetically transmitted in the great majority of patients. Management during pregnancy and delivery is guided by the same general principles and management of ISM in general, with primary reliance on H1 and H2 antihistamines, glucocorticoids as needed to control exacerbations, oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> for gastrointestinal symptoms, antileukotriene agents, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> if necessary, and sparing use of cytoreductive agents if symptoms cannot be controlled with other measures [<a href="#rid22">22</a>]. Avoidance of anaphylaxis is particularly critical during pregnancy as hypotension can disproportionately impact the fetus, and anaphylaxis may induce uterine cramping. (See  <a class="medical medical_review" href="/z/d/html/393.html" rel="external">"Anaphylaxis during pregnancy and delivery", section on 'Consequences'</a>.)</p><p>Very symptomatic patients should be managed by a multidisciplinary team, including high-risk obstetrics. Labor and delivery are approached similarly to other procedures, with avoidance of triggering medications when possible (see <a class="local">'Problematic medications'</a> above). Breastfeeding mothers should review medications with a clinician or lactation consultant to ensure that all agents are safe for infants (eg, sedating antihistamines should be avoided).</p><p class="headingAnchor" id="H290412881"><span class="h1">SPECIALIST INVOLVEMENT</span><span class="headingEndMark"> — </span>Patients with well-controlled symptoms on antimediator therapy and stable complete blood count (CBC) with differential and tryptase levels can be followed by their primary care clinician. Referral to a specialist with expertise in mast cell disorders should be pursued for patients who remain symptomatic despite antimediator therapy, have an increase in skin lesions, a change in labs (increased tryptase or abnormal CBC with differential), develop new clinical symptoms (eg, weight loss, bone fracture, anaphylaxis), or may be candidates for clinical trials.</p><p>Referral to an allergist is appropriate for patients with recurrent anaphylaxis or concurrent IgE-mediated allergies (such as Hymenoptera or food).</p><p class="headingAnchor" id="H457997708"><span class="h1">THERAPIES TO CONTROL SYMPTOMS</span><span class="headingEndMark"> — </span>Patients with ISM and SSM can be very symptomatic. Quality-of-life questionnaires have been developed and can be used to assess symptoms [<a href="#rid23">23,24</a>]. One study found that a majority report some degree of functional limitation, with approximately one-sixth reporting extreme limitations [<a href="#rid25">25</a>]. A patient survey found more than two-thirds of the respondents were symptomatic with itching, flushing, fatigue, and stomach pain [<a href="#rid26">26</a>]. The following therapies may be needed for symptomatic patients with any subtype of SM. Symptoms arising from mediator release are most prominent in patients with ISM and SSM but can occur in more advanced subtypes.</p><p class="headingAnchor" id="H125830779"><span class="h2">Therapies for all patients</span><span class="headingEndMark"> — </span>H1 and H2 antihistamines and antileukotriene drugs are helpful for nearly all patients.</p><p class="headingAnchor" id="H3078620050"><span class="h3">Antihistamines</span><span class="headingEndMark"> — </span>Initial pharmacologic treatment includes the use of H1 and H2 antihistamines. H1 antihistamines are administered to prevent flushing and itching. H2 antihistamines are helpful in controlling abdominal pain, heartburn, cramping, and/or diarrhea.</p><p class="bulletIndent1"><span class="glyph">●</span>H1 antihistamines (adult dosing) include oral <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> (10 to 40 mg daily), <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a> (180 to 360 mg daily), <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a> (10 to 40 mg daily), <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> (25 mg every six hours), or <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">doxepin</a> (10 to 100 mg per day) [<a href="#rid2">2</a>]. In some patients, a combination of two or more H1 antihistamines or increasing the standard dose of a nonsedating agent may provide better symptom control. <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">Diphenhydramine</a> (25 to 50 mg up to four times daily) may be added on an as-needed basis to manage breakthrough symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>H2 antihistamines (adult dosing) include oral <a class="drug drug_general" data-topicid="8436" href="/z/d/drug information/8436.html" rel="external">famotidine</a> (20 mg twice daily) and <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a> (300 mg twice daily) [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">Ketotifen</a>, which has been reported to have both mast cell-stabilizing and H1 antihistamine properties, may be administered where available (eg, Canada and Europe), although it can be quite sedating for some patients, and they should be cautioned about this side effect. This drug is not available in oral form in the United States, although it can be compounded. The adult dose is 1 to 4 mg orally every 12 hours [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H3913253552"><span class="h3">Antileukotriene drugs</span><span class="headingEndMark"> — </span>Antileukotriene agents (eg, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> 10 mg daily, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> 20 mg daily, or <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> 1200 mg twice daily) may be added in patients with flushing, itching, or abdominal cramping unresponsive to H1 and H2 antihistamines [<a href="#rid28">28</a>]. The patient should be warned about psychiatric adverse effects.</p><p class="headingAnchor" id="H1906026818"><span class="h2">Additional therapies for specific problems</span><span class="headingEndMark"> — </span>Additional issues may arise that require specific interventions.</p><p class="headingAnchor" id="H2616553728"><span class="h3">Recurrent anaphylaxis</span><span class="headingEndMark"> — </span>For patients with SM who experience recurrent anaphylaxis or mast cell activation symptoms with hemodynamic instability despite trigger avoidance, maximized doses of antimediator agents (H1 and H2 antihistamines and antileukotriene drugs) should be prescribed. If episodes of anaphylaxis persist, the therapies below may be helpful, based on anecdotal clinical experience and indirect evidence.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omalizumab</strong> – <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a> (anti-IgE), a humanized monoclonal antibody that inhibits the binding of IgE to mast cells, reduced the frequency of anaphylaxis in some patients with SM or monoclonal mast cell activation syndrome [<a href="#rid29">29,30</a>]. Omalizumab therapy was also reported to improve cutaneous and neurologic symptoms in a patient with urticaria pigmentosa who did not undergo bone marrow evaluation and so was not conclusively diagnosed with SM [<a href="#rid31">31</a>]. The use of omalizumab for these indications is not approved by the US Food and Drug Administration (FDA) but deserves further study. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – Glucocorticoids appear to reduce mast cell numbers through inhibition of stem cell factor synthesis [<a href="#rid32">32</a>]. For patients with recurrent anaphylaxis, if <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> is not available or a more rapid intervention is needed (eg, because the patient is having several episodes per month), a slowly tapering course of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> may be effective. The author's approach is to begin with 20 to 30 mg daily in adults, given for two to three weeks. Higher initial doses can be problematic and may cause flushing, tachycardia, and abdominal pain, side effects that can be difficult to differentiate from mast cell mediator effects. This is followed by a slow taper (eg, by 5 to 10 mg per week). Some patients may require low-dose maintenance therapy, such as 5 to 10 mg daily in this setting.</p><p></p><p class="headingAnchor" id="H3861684093"><span class="h3">Flushing</span><span class="headingEndMark"> — </span>In patients with prominent flushing not responsive to antihistamines, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may be helpful, provided the patient is known to tolerate nonsteroidal antiinflammatory drugs (NSAIDs) [<a href="#rid2">2</a>]. NSAIDs trigger mediator release in some patients, and these individuals should avoid them. Although aspirin can reduce flushing, high doses may be needed (up to 500 mg once or twice daily) and may not be tolerated by patients already predisposed to peptic ulcer disease [<a href="#rid33">33</a>].</p><p>If the patient's tolerance of NSAIDs is not known, the first dose of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> should be administered in a supervised setting. We typically give an initial dose of 81 mg, followed by 325 mg, allowing 90 minutes after each step to observe for symptoms. Emergency medications and equipment should be available. If symptoms develop or if the patient has a history of NSAID allergy or intolerance, the patient is not a candidate for aspirin therapy, and we do not recommend attempting desensitization.</p><p class="headingAnchor" id="H3373393928"><span class="h3">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>Gastrointestinal symptoms in patients with SM may be treated with oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> sodium, H2 antihistamines, and proton pump inhibitors (PPIs).</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">Cromolyn</a> sodium is available as an oral concentrate (100 mg per 5 mL vial) and may be administered by giving one to two vials in a glass of water, drunk four times daily prior to meals and bedtime [<a href="#rid34">34</a>]. Oral cromolyn should be initiated at the lower end of the dose range and gradually increased as it is minimally absorbed through the intestine and can cause osmotic diarrhea in some patients if introduced at high doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>H2 antihistamines are helpful in patients with symptoms of hyperacidity and abdominal pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PPIs may be added to H2 antihistamines in patients with peptic ulcer disease or those with abdominal complaints unresponsive to antihistamines alone. If this is needed, the H2 antihistamine and PPI should be administered at different times. As an example, the PPI can be given in the morning before the first meal of the day, and an H2 antagonist can be given several hours later and before bed or vice versa. (See  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"</a>.)</p><p></p><p>Intractable diarrhea may be treated with oral or topical steroids. There are no studies examining optimal dosing. We typically start with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg daily dose and attempt to taper it over the following two to three weeks. Efficacy of oral <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> has been suggested but not studied.</p><p class="headingAnchor" id="H1182862937"><span class="h3">Osteoporosis and fractures</span><span class="headingEndMark"> — </span>Patients with all forms of SM should be monitored for osteopenia and osteoporosis and treated appropriately [<a href="#rid35">35-39</a>]. Management in patients with SM is essentially the same as that in patients without SM. In patients with normal bone density, we repeat densitometry in three years. Appropriate daily intake of calcium and vitamin D should be maintained. For patients with osteoporosis-related fractures, treatment with the combination of bisphosphonate and low-dose interferon alfa has been reported to be helpful [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p class="headingAnchor" id="H28386977"><span class="h3">Cutaneous pruritus refractory to antihistamines</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> ointment, topical corticosteroids, and narrowband ultraviolet B (UVB) phototherapy have been used with variable success for patients whose symptoms were not controlled with oral antihistamines and antileukotriene agents. These therapies are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4785.html" rel="external">"Cutaneous mastocytosis: Treatment, monitoring, and prognosis"</a>.)</p><p class="headingAnchor" id="H239836278"><span class="h1">CYTOREDUCTIVE AGENTS FOR REFRACTORY SYMPTOMS</span><span class="headingEndMark"> — </span>For patients with recurrent anaphylaxis or multisystem moderate-to-severe symptoms that cannot be controlled with other measures, there is a role for mast cell cytoreductive therapies. A detailed conversation about potential benefits and adverse effects should inform shared decision-making with the patient. Specifically, the clinician should explain that all cytoreductive therapies carry potential risks that are not present with symptom-controlling therapies, and the risks of the specific agent under consideration should be carefully reviewed. Detailed discussions of the toxicities of the cytoreductive agents used in mast cell diseases are reviewed briefly here and in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis", section on 'Medical therapies'</a>.)</p><p class="headingAnchor" id="H3379041596"><span class="h2">Avapritinib</span><span class="headingEndMark"> — </span>For patients with moderate-to-severe symptoms despite optimal symptom-directed therapies (including <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> if available), we add <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a> in preference to other cytoreductive agents. Avapritinib (BLU-285) is an oral inhibitor of D816V-mutated <em>KIT, </em>which is present in &gt;90 percent of patients with ISM. Avapritinib is the only cytoreductive agent approved by US Food and Drug Administration (FDA) for the indication of ISM [<a href="#rid41">41</a>]. It was shown to reduce total symptom scores (TSS) as well as serum tryptase levels and other markers of mast cell burden in a randomized trial of 212 patients with ISM and uncontrolled symptoms despite best supportive care [<a href="#rid42">42</a>]. Patients were randomized two to one to avapritinib (25 mg daily) or placebo for 24 weeks. Supportive care included at least two of the following medications: H1 and H2 antihistamines, leukotriene inhibitors, proton pump inhibitors (PPIs), glucocorticoids (20 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> daily or less), oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> sodium, omalizumab, and osteoclast inhibitors. The primary endpoint was the mean change in TSS. At screening, patients had TSS ≥28 (on a scale of 0 to 110, with higher scores indicating more severe symptoms). Quality-of-life scores and reductions of ≥30 and 50 percent in TSS were among secondary endpoints, with a ≥30 percent reduction considered a clinically important response for an individual patient.</p><p>Baseline mean TSS was similar in both treatment and placebo groups at 50 and 52 points, respectively [<a href="#rid42">42</a>]. Avapritinib-treated patients had a decrease of 15.6 points (95% CI −18.6 to −12.6) in TSS compared with a decrease of 9.2 points (−13.1 to −5.2) in the placebo group. Among patients receiving <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a>, 25 and 45 percent achieved ≥30 and ≥50 percent reductions in TSS compared with 10 and 30 percent of patients receiving placebo. Best supportive care medications could be reduced/discontinued in 24 and 13 percent of avapritinib-treated and placebo-treated patients, respectively.</p><p>Longer-term safety data on the use of <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a> in patients with ISM are needed and are under investigation. Edema, flushing, and elevations in alkaline phosphatase were more common with avapritinib than placebo, with three people discontinuing treatment due to adverse effects in the avapritinib versus one in the placebo group [<a href="#rid42">42</a>]. Avapritinib is not recommended for patients with platelet counts &lt;50,000/microL, because of an increased potential risk of intracranial hemorrhage in these patients (based on studies of patients with advanced SM being treated with higher doses). Avapritinib may impair fertility based on animal data, and males and females of reproductive potential must use contraception because avapritinib can cause fetal harm.</p><p class="headingAnchor" id="H3774113449"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>If <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a> is ineffective or unavailable, we suggest participation in a clinical trial, when possible. Trials of elenestinib (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05609942&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOCvtMG49KJF%2BVtc7WU%2F0kjFhCgdSKd4nO7v47qvPWm3w%3D%3D&amp;TOPIC_ID=118890" target="_blank">NCT05609942</a>) and bezuclastinib (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05186753&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPMQNlIoQ7%2BVESJXb4n04Izv0D%2FiyGilPzoSZGLOt%2FiyPA%3D%3D&amp;TOPIC_ID=118890" target="_blank">NCT05186753</a>) are ongoing. <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">Midostaurin</a>, <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, or interferon alfa are other available options.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Midostaurin</strong> – <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">Midostaurin</a> is a multi-kinase/KIT inhibitor that inhibits the protein product of <em>KIT</em>, including the kinase encoded by D816V-mutated <em>KIT</em>. Although not approved by the US FDA for ISM, it was shown to alleviate symptoms in an open-label study of 20 patients with ISM or SSM [<a href="#rid43">43</a>]. The most common adverse effects of midostaurin are nausea and vomiting, which may limit its tolerability in patients with ISM. Bone marrow suppression may also occur. The use of midostaurin in advanced forms of SM is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cladribine</strong><strong> or interferon alfa</strong> – If other options are not available, 2-chlorodeoxyadenosine (<a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>/2-CdA) or interferon alfa may also be trialed [<a href="#rid3">3,44,45</a>]. Use of these agents is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">"Advanced systemic mastocytosis: Management and prognosis", section on 'Other agents'</a>.)</p><p></p><p class="headingAnchor" id="H2366638532"><span class="h1">TREATMENT OF COEXISTENT ALLERGIC DISEASE</span><span class="headingEndMark"> — </span>Patients with SM develop allergic diseases at a rate similar to that of the general population and may experience anaphylaxis to Hymenoptera venom (honey bee, wasp, hornet, yellow jacket, or fire ant stings), as well as allergic rhinitis, asthma, and food and drug allergies [<a href="#rid4">4,46-48</a>]. The treatment of allergic disorders in SM patients may need to be modified in individuals who are prone to episodes of mast cell activation.</p><p class="headingAnchor" id="H2079089658"><span class="h2">Hymenoptera venom allergy</span><span class="headingEndMark"> — </span>Patients with mastocytosis can suffer severe anaphylaxis in response to an insect sting [<a href="#rid49">49-52</a>]. Fatalities have been reported in patients with SM who were stung by Hymenoptera despite self-treatment with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid53">53</a>]. Thus, patients with anaphylaxis following a known or possible Hymenoptera sting should be evaluated with skin tests or in vitro tests for venom-specific IgE, and, if found to be sensitized, they should be offered venom immunotherapy (VIT). (See  <a class="medical medical_review" href="/z/d/html/4090.html" rel="external">"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action"</a> and  <a class="medical medical_review" href="/z/d/html/4096.html" rel="external">"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/4095.html" rel="external">"Diagnosis of Hymenoptera venom allergy"</a>.)</p><p>The benefits of VIT in patients with SM appear to outweigh the risks of systemic allergic reactions to the therapy itself, which can be increased in patients with SM compared with those without SM. Patients should be counseled about this when giving consent to receive VIT. Most experts agree that the duration of VIT should be lifelong [<a href="#rid50">50</a>]. Safety measures during administration of VIT include starting with a less concentrated venom preparation (ie, 0.01 to 0.1 micrograms/mL) and premedicating with an H1 antihistamine on the day of each injection. <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> should be available to treat potential systemic reactions. (See  <a class="medical medical_review" href="/z/d/html/4096.html" rel="external">"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring"</a>.)</p><p>Safety and efficacy were evaluated in retrospective series:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 21 subjects with mastocytosis who underwent VIT, 12 patients were re-stung during treatment, and 9 of them developed only local reactions, suggesting protection against repeat anaphylaxis [<a href="#rid49">49</a>]. However, 30 percent experienced adverse reactions during the build-up phase of immunotherapy, most of which involved hypotension in combination with other symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VIT was also evaluated in a retrospective study of 46 patients: 22 with SM, 10 with monoclonal mast cell activation syndrome, and 14 controls without mast cell disorders [<a href="#rid54">54</a>]. Approximately 34 percent of patients with mast cell disorders experienced adverse reactions to VIT compared with 7 percent of controls, although only one SM patient suffered anaphylaxis. Patient-based protection from anaphylaxis was 76 percent and 100 percent in patients with mast cell disorders and controls, respectively. Venom-specific immunoglobulin G4 (IgG4) levels correlated with protection from anaphylaxis, as has been noted before with VIT. (See  <a class="medical medical_review" href="/z/d/html/362.html" rel="external">"Allergen immunotherapy for allergic disease: Therapeutic mechanisms", section on '"Blocking" IgG4'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a> has been administered before initiating VIT to reduce the risk of systemic reactions to the treatment injections. A case report described a patient with SM who suffered near-fatal anaphylaxis to a Hymenoptera sting and was begun on VIT but then experienced repeated systemic reactions to the injections and was unable to reach maintenance doses [<a href="#rid55">55</a>]. Omalizumab was administered one week prior to his subsequent venom injection at a dose of twice what is generally indicated for the treatment of asthma. Using this approach before each monthly injection, he was able to advance immunotherapy to the effective dose. Subsequent attempts to lower the dose of omalizumab or to extend the time between maintenance injections beyond 30 days resulted in recurrent systemic reactions [<a href="#rid56">56</a>]. The patient sustained later Hymenoptera stings without reacting. However, another case report described a patient in whom omalizumab was administered to prevent systemic reactions to VIT, but the patient was not able to tolerate VIT once omalizumab was discontinued [<a href="#rid57">57</a>]. In the United States, omalizumab is not approved for this use, although the drug can sometimes be obtained on a compassionate-use basis in individual cases.</p><p class="headingAnchor" id="H1594591750"><span class="h2">Allergic rhinitis and asthma</span><span class="headingEndMark"> — </span>Patients with SM and allergic rhinitis, conjunctivitis, and/or asthma are managed with the same medications as patients without SM, although dosing requirements may be higher. We generally avoid the use of subcutaneous immunotherapy (SCIT) for respiratory allergy, as patients with SM are at greater risk for systemic reactions and anaphylaxis as a consequence of the therapy itself, and the benefit conferred by immunotherapy for respiratory disease is not as great as that for venom allergy. The safety of SCIT with inhalant allergens in patients with SM has not been formally studied. (See  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="headingAnchor" id="H1436013404"><span class="h1">MONITORING FOR PROGRESSION</span></p><p class="headingAnchor" id="H1350750975"><span class="h2">Indolent systemic mastocytosis</span><span class="headingEndMark"> — </span>Yearly monitoring is appropriate for uncomplicated patients with ISM, a normal physical examination (other than skin lesions), and stable weight, although the frequency of evaluation should be increased if symptoms worsen or new signs/symptoms appear:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum tryptase levels, which reflect mast cell burden.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with differential to monitor for changes in leukocytes, platelets, and eosinophils, as well as abnormal forms, since advanced forms of SM can be associated with other hematologic malignancies. New abnormalities of the CBC should prompt repeat evaluation for a more advanced form of disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum chemistry panel to monitor for liver involvement and electrolyte imbalances. Elevation of the serum alkaline phosphatase level is the most common presentation of liver involvement by mast cell disease.</p><p></p><p>Changes in any of these tests, weight loss, or the development of splenomegaly should prompt evaluation for advanced forms of the disease. Serum levels of beta-2 microglobulin have been identified as an independent predictor of progression but need further validation. (See  <a class="medical medical_review" href="/z/d/html/103174.html" rel="external">"Systemic mastocytosis: Determining the subtype of disease"</a>.)</p><p>Changes in the appearance of skin lesions in patients with maculopapular cutaneous mastocytosis (MPCM) do not necessarily correlate with changes in the underlying disease. Approximately 10 to 15 percent of patients with ISM and MPCM may experience a regression of skin lesions, which may correspond to either improvement or worsening in the systemic disease [<a href="#rid58">58</a>]. Similarly, increases in MPCM lesions, even dramatic increases, do not necessitate additional evaluation if the patient is feeling well.</p><p class="headingAnchor" id="H3028128276"><span class="h2">Smoldering systemic mastocytosis</span><span class="headingEndMark"> — </span>Patients with SSM are generally seen and monitored every six months using the same approach as that for patients with ISM or more frequently if there are signs/symptoms of progression. The development of unexplained hematologic abnormalities (eg, increased white blood count, immature forms, monocytosis, increased or decreased platelets), hepatosplenomegaly, unexplained weight loss, coagulopathy, ascites, or gastrointestinal bleeding should alert the clinician to the possibility of disease progression.</p><p class="headingAnchor" id="H1282604554"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H846752463"><span class="h2">Morbidity from anaphylaxis</span><span class="headingEndMark"> — </span>A primary concern in the management of ISM is anaphylaxis, as severe disability and death have been reported [<a href="#rid3">3</a>]. Risk factors and triggers are reviewed above. (See <a class="local">'Elevated risk of anaphylaxis'</a> above.)</p><p class="headingAnchor" id="H3339021442"><span class="h2">Risk of progression</span><span class="headingEndMark"> — </span>The category of SM is the single most important prognostic factor. Other prognostic factors include molecular abnormalities, beta-2 microglobulin levels, allelic frequency, and presence of KIT D816V mutation in multiple cell lineages [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H155111959"><span class="h3">By disease category</span><span class="headingEndMark"> — </span>Most patients with ISM have a normal life expectancy [<a href="#rid59">59,60</a>]. Approximately 3 percent of patients with an initial diagnosis of ISM will progress to a more severe form of SM, including SM with an associated hematologic neoplasm (SM-AHN), aggressive systemic mastocytosis (ASM), or mast cell leukemia (MCL) [<a href="#rid59">59</a>].</p><p>Among patients with SSM, 18 percent progressed to ASM or MCL in a large study [<a href="#rid60">60</a>]. Of note, these data are from a single-institution retrospective analysis of 342 patients with all types of SM followed for a median of 21 months (range 0 to 35 years), and there may have been referral bias for more severe disease in this study [<a href="#rid60">60-62</a>]. In addition, the shorter life expectancy observed in patients with SSM may be due to older age at diagnosis [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H936875866"><span class="h3">Molecular abnormalities</span><span class="headingEndMark"> — </span>Next-generation sequencing myeloid mutation panels performed at the time of diagnosis can provide prognostic information. In a series of 200 patients from two referral centers with ISM who were followed for a median of nine years, 7 percent progressed to more advanced forms of SM, including five who developed SSM. All who progressed exhibited <em>KIT</em> mutation of bone marrow (BM) cells with variant allele frequency (VAF) ≥1 percent; pathogenic mutations of <em>ASXL1, RUNX1</em>, and/or <em>DNMT3A</em> (<em>A/R/D</em>) with VAF ≥30 percent; and/or elevated baseline tryptase levels [<a href="#rid64">64</a>]. Reduced progression-free survival was independently associated with <em>KIT</em> D816V VAF ≥1 percent in the BM (hazard ratio [HR] 12, 95% CI 1.3-108), serum beta-2 microglobulin ≥2.5 mcg/mL (HR 9.8, 95% CI 2.6-3.6), and <em>A/R/D</em> VAF ≥30 percent (HR 4, 95% CI 1.2-10) in multivariate analysis. Lower overall survival was independently associated only with <em>A/R/D</em> VAF ≥30 percent (HR 52, 95% CI 4-647). Findings were validated in a separate cohort of 122 patients. (See  <a class="medical medical_review" href="/z/d/html/103174.html" rel="external">"Systemic mastocytosis: Determining the subtype of disease", section on 'Advanced testing'</a>.)</p><p class="headingAnchor" id="H1775358383"><span class="h3">Other poor prognostic factors</span><span class="headingEndMark"> — </span>Certain clinical features are associated with an increased risk of death due to disease progression, independent of the category of SM present, including the following [<a href="#rid60">60,65,66</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Older age at onset of systemic symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated lactate dehydrogenase (LDH)</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated alkaline phosphatase</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenomegaly</p><p></p><p>Understanding of the significance of skin lesions is evolving. Historically, the absence of maculopapular cutaneous mastocytosis (MPCM; formerly called urticaria pigmentosa) was believed to be a poor prognostic indicator in patients who fulfilled World Health Organization criteria for SM. However, now that more patients without cutaneous involvement are being diagnosed with ISM, absent skin lesions do not appear to reflect a poor prognosis. For example, less than 50 percent of patients with SM presenting with Hymenoptera sting anaphylaxis have MPCM or other forms of cutaneous mastocytosis, yet this subset of patients does not appear to have a worse prognosis or to be at increased risk for disease progression [<a href="#rid49">49</a>]. In addition, one study indicated that some patients with ISM who initially presented with MPCM lesions may lose the lesions over time and have an excellent prognosis, even those who demonstrate the D816V mutation [<a href="#rid58">58,67</a>].</p><p class="headingAnchor" id="H3048629492"><span class="h2">Increased risk for other disorders</span><span class="headingEndMark"> — </span>In a Danish registry of 687 adults with SM diagnosed between 1997 and 2012, patients were found to have an increased risk for several other disorders compared with those without SM [<a href="#rid68">68</a>]. In addition to anaphylaxis, osteoporosis, and fractures, HRs in the patient cohort were dramatically increased for melanoma and nonmelanoma skin cancers. This may have been in part due to previous phototherapy, but further study is required.</p><p class="headingAnchor" id="H3351205279"><span class="h1">INVESTIGATIONAL AGENTS</span><span class="headingEndMark"> — </span>Information and instructions for referring a patient to an appropriate research center can be obtained from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=118890" target="_blank">ClinicalTrials.gov</a>. Investigational agents include masitinib and monoclonal antibodies [<a href="#rid69">69,70</a>].</p><p class="headingAnchor" id="H3725846395"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109417.html" rel="external">"Society guideline links: Mast cell disorders"</a>.)</p><p class="headingAnchor" id="H3201499902"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>Information for patients, including lists of triggers for mast cell degranulation, is available online on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftmsforacure.org%2F&amp;token=6IUAent2pV6XNor4WxQLPP0JX8FuPzQs4nMDaN1d3JyvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=118890" target="_blank">Mastocytosis Society website</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nih.gov%2Fabout-nih%2Fwhat-we-do%2Fnih-almanac%2Fnational-institute-allergy-infectious-diseases-niaid&amp;token=eK7PdGW4BPeG1xKQsNTxiqHnkyfihzTUJnk65lSaVIt6an3w29%2B0oZUvYFRfSkIek8gyVkbNu03IVwewsXlBc0kfiaBYGv0w1%2FjGHrCdcJD2GG2GA4qQyjLWLfXrvexF&amp;TOPIC_ID=118890" target="_blank">National Institute of Allergy and Infectious Diseases website</a>. Additional information is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frarediseases.info.nih.gov%2Fabout%2F&amp;token=9E9IX7kiH9qRiTPgEvfhBWYEK1xv9pzeICuXRSzlhQr4OKPwDtNBnRks6AeMyB6YrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=118890" target="_blank">National Institutes of Health Genetic and Rare Diseases (GARD)</a> website.</p><p class="headingAnchor" id="H637159023"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indolent and smoldering subtypes of systemic mastocytosis</strong> – Systemic mastocytosis (SM) is a rare and heterogeneous disorder in which patients are classified into one of five subtypes  (<a class="graphic graphic_table graphicRef82828" href="/z/d/graphic/82828.html" rel="external">table 1</a>). Indolent systemic mastocytosis (ISM) accounts for more than 50 percent of all SM cases in the published literature, while smoldering systemic mastocytosis (SSM) is rare. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent anaphylaxis is more common in ISM compared with other subtypes</strong> – Although patients with any form of SM may experience episodic symptoms of mast cell activation and anaphylaxis, these symptoms are more common in ISM and SSM, with up to one-half of patients experiencing anaphylaxis. Anaphylaxis represents the primary threat to patients with these variants of disease. A variety of exposures may trigger symptoms, including physical factors, alcohol, medications, emotional stress, insect stings, and allergens. All patients should be equipped with <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors and carry at least two doses at all times. (See <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom-specific pharmacotherapy </strong>– Pharmacotherapy for most patients includes H1 and H2 antihistamines, antileukotriene drugs, and <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> sodium, with additional treatments as needed for specific disorders, such as flushing, gastrointestinal disorders, osteoporosis, or depression. (See <a class="local">'Therapies to control symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of anaphylaxis </strong>– For patients with recurrent anaphylaxis or episodes of mast cell activation symptoms with hemodynamic instability despite trigger avoidance and maximized doses of H1 and H2 antihistamines and antileukotriene drugs, we suggest <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> rather than oral glucocorticoids or a cytoreductive agent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Recurrent anaphylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytoreductive therapy for patients with refractory symptoms </strong>– For patients with moderate-to-severe symptoms despite optimal symptom-directed therapies (including <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> if available), we suggest adding <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">avapritinib</a> rather than only treating with symptom-directed therapy or adding a different cytoreductive agent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Cytoreductive agents for refractory symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with coexisting allergic disorders</strong> – Patients with SM develop allergic diseases at a rate similar to that of the general population. Management depends upon the type of allergy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stings of Hymenoptera insects (bees, wasps, fire ants, etc) in patients with ISM can be fatal. For patients with Hymenoptera venom-induced anaphylaxis and positive skin tests or in vitro tests to venom, we suggest lifelong venom immunotherapy (VIT), despite the higher risk of allergic reactions induced by the injections (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Hymenoptera venom allergy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with allergic rhinitis or asthma due to environmental allergies, we typically do not administer subcutaneous immunotherapy (SCIT), as these conditions can be managed with medications and the risk of systemic reactions to the injections usually outweighs the additional benefit of the immunotherapy. (See <a class="local">'Treatment of coexistent allergic disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring </strong>– Patients with ISM and SSM should be followed regularly with a review of systems and laboratory testing to detect signs and symptoms of disease progression. Osteopenia and osteoporosis are common complications, and screening, prevention, and treatment are important. (See <a class="local">'Monitoring for progression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Patients with ISM have a near-normal life expectancy, with less than 3 percent of patients progressing to a more severe form of SM. In these patients, disability or death from anaphylaxis often represents the greater threat. Patients with SSM are at higher risk for progression, although data are limited. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000; 14:659.</a></li><li><a class="nounderline abstract_t">Wimazal F, Geissler P, Shnawa P, et al. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 2012; 157:399.</a></li><li><a class="nounderline abstract_t">González de Olano D, de la Hoz Caballer B, Núñez López R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37:1547.</a></li><li><a class="nounderline abstract_t">Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.</a></li><li><a class="nounderline abstract_t">Florian S, Krauth MT, Simonitsch-Klupp I, et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol 2005; 136:273.</a></li><li><a class="nounderline abstract_t">Akin C. Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep 2010; 10:34.</a></li><li><a class="nounderline abstract_t">Gülen T, Ljung C, Nilsson G, Akin C. Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis. J Allergy Clin Immunol Pract 2017; 5:1248.</a></li><li><a class="nounderline abstract_t">Turk J, Oates JA, Roberts LJ 2nd. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983; 71:189.</a></li><li><a class="nounderline abstract_t">Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12:259.</a></li><li><a class="nounderline abstract_t">Carter MC, Uzzaman A, Scott LM, et al. Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 2008; 107:422.</a></li><li><a class="nounderline abstract_t">James PD, Krafchik BR, Johnston AE. Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth 1987; 34:522.</a></li><li><a class="nounderline abstract_t">Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2019; 143:880.</a></li><li><a class="nounderline abstract_t">Bonadonna P, Brockow K, Niedoszytko M, et al. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). J Allergy Clin Immunol Pract 2021; 9:2139.</a></li><li><a class="nounderline abstract_t">Parente R, Pucino V, Magliacane D, et al. Evaluation of vaccination safety in children with mastocytosis. Pediatr Allergy Immunol 2017; 28:93.</a></li><li><a class="nounderline abstract_t">Johansen ML, Lawley LP. Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mastocytosis. Pediatr Dermatol 2021; 38:502.</a></li><li><a class="nounderline abstract_t">Zanoni G, Zanotti R, Schena D, et al. Vaccination management in children and adults with mastocytosis. Clin Exp Allergy 2017; 47:593.</a></li><li><a class="nounderline abstract_t">Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol 2021; 147:877.</a></li><li><a class="nounderline abstract_t">Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract 2021; 9:3198.</a></li><li><a class="nounderline abstract_t">Rosman Y, Lavi N, Meir-Shafrir K, et al. Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders. J Allergy Clin Immunol Pract 2021; 9:3487.</a></li><li><a class="nounderline abstract_t">Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. Obstet Gynecol 2000; 95:391.</a></li><li><a class="nounderline abstract_t">Lei D, Akin C, Kovalszki A. Management of Mastocytosis in Pregnancy: A Review. J Allergy Clin Immunol Pract 2017; 5:1217.</a></li><li><a class="nounderline abstract_t">van Anrooij B, Kluin-Nelemans JC, Safy M, et al. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy 2016; 71:1585.</a></li><li><a class="nounderline abstract_t">Siebenhaar F, von Tschirnhaus E, Hartmann K, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy 2016; 71:869.</a></li><li><a class="nounderline abstract_t">Hermine O, Lortholary O, Leventhal PS, et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 2008; 3:e2266.</a></li><li><a class="nounderline abstract_t">Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract 2014; 2:70.</a></li><li><a class="nounderline abstract_t">Póvoa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. J Intern Med 1991; 229:475.</a></li><li><a class="nounderline abstract_t">Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004; 350:735.</a></li><li><a class="nounderline abstract_t">Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119:1550.</a></li><li><a class="nounderline abstract_t">Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol 2014; 113:115.</a></li><li><a class="nounderline abstract_t">Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol 2007; 120:213.</a></li><li><a class="nounderline abstract_t">Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997; 99:1721.</a></li><li><a class="nounderline abstract_t">Butterfield JH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009; 88:122.</a></li><li><a class="nounderline abstract_t">Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990; 85:852.</a></li><li><a class="nounderline abstract_t">Rossini M, Zanotti R, Bonadonna P, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011; 49:880.</a></li><li><a class="nounderline abstract_t">Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69:1838.</a></li><li><a class="nounderline abstract_t">Lim AY, Ostor AJ, Love S, Crisp AJ. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 2005; 64:965.</a></li><li><a class="nounderline abstract_t">Rossini M, Zanotti R, Viapiana O, et al. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 2014; 127:1127.e1.</a></li><li><a class="nounderline abstract_t">Greene LW, Asadipooya K, Corradi PF, Akin C. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord 2016; 17:419.</a></li><li><a class="nounderline abstract_t">Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011; 124:776.</a></li><li class="breakAll">Supplement Approval: Fulfillment of postmarketing requirement. Ayvakit (avapritinib) tablets. US Food &amp; Drug Administration (FDA) approval letter. May 22, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/212608Orig1s013ltr.pdf (Accessed on May 29, 2023).</li><li><a class="nounderline abstract_t">Gotlib J, Castells M, Elberink HO, et al. Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid 2023; 2.</a></li><li><a class="nounderline abstract_t">van Anrooij B, Oude Elberink JNG, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. J Allergy Clin Immunol 2018; 142:1006.</a></li><li><a class="nounderline abstract_t">Giraldo Castellano P, García-Erce JA, Alvarez Alegret R, et al. [Interferon alpha and systemic mastocytosis. Analysis of therapeutic efficacy in 6 cases]. Rev Clin Esp 1998; 198:345.</a></li><li><a class="nounderline abstract_t">Tefferi A, Kittur J, Farrukh F, et al. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol 2022; 196:975.</a></li><li><a class="nounderline abstract_t">Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003; 48:508.</a></li><li><a class="nounderline abstract_t">Müller U, Helbling A, Hunziker T, et al. Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa. Allergy 1990; 45:597.</a></li><li><a class="nounderline abstract_t">Greenhawt M, Akin C. Mastocytosis and allergy. Curr Opin Allergy Clin Immunol 2007; 7:387.</a></li><li><a class="nounderline abstract_t">González de Olano D, Alvarez-Twose I, Esteban-López MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519.</a></li><li><a class="nounderline abstract_t">Niedoszytko M, de Monchy J, van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237.</a></li><li><a class="nounderline abstract_t">Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008; 121:256.</a></li><li><a class="nounderline abstract_t">Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680.</a></li><li><a class="nounderline abstract_t">Ruëff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284.</a></li><li><a class="nounderline abstract_t">Jarkvist J, Salehi C, Akin C, Gülen T. Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection. Allergy 2020; 75:169.</a></li><li><a class="nounderline abstract_t">Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376.</a></li><li><a class="nounderline abstract_t">Kontou-Fili K, Filis CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009; 64:1384.</a></li><li><a class="nounderline abstract_t">Jandus P, Hausmann O, Haeberli G, et al. Unpredicted adverse reaction to omalizumab. J Investig Allergol Clin Immunol 2011; 21:563.</a></li><li><a class="nounderline abstract_t">Brockow K, Scott LM, Worobec AS, et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002; 138:785.</a></li><li><a class="nounderline abstract_t">Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124:514.</a></li><li><a class="nounderline abstract_t">Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113:5727.</a></li><li><a class="nounderline abstract_t">Pardanani A. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015; 90:250.</a></li><li><a class="nounderline abstract_t">Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 2016; 91:1146.</a></li><li><a class="nounderline abstract_t">Tefferi A, Shah S, Reichard KK, et al. Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis. Am J Hematol 2019; 94:E1.</a></li><li><a class="nounderline abstract_t">Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, et al. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood 2019; 134:456.</a></li><li><a class="nounderline abstract_t">Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91:612.</a></li><li><a class="nounderline abstract_t">Butterfield JH, Weiler CR. Systemic mastocytosis in the elderly. Am J Hematol 2013; 88:406.</a></li><li><a class="nounderline abstract_t">Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One 2008; 3:e1906.</a></li><li><a class="nounderline abstract_t">Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. Am J Hematol 2016; 91:1069.</a></li><li><a class="nounderline abstract_t">Lortholary O, Chandesris MO, Bulai Livideanu C, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 2017; 389:612.</a></li><li class="breakAll">https://www.allakos.com/pipeline/ (Accessed on August 30, 2019).</li></ol></div><div id="topicVersionRevision">Topic 118890 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10909045" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of systemic mast cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123213" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17883734" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186813" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15722637" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20425512" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaphylaxis and mast cell disease: what is the risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28351784" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6296213" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intervention with epinephrine in hypotension associated with mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668033" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633019" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pediatric mastocytosis: routine anesthetic management for a complex disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3664922" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cutaneous mastocytosis in children: anaesthetic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528617" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831618" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27590431" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of vaccination safety in children with mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33393144" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079293" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vaccination management in children and adults with mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33485650" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34033981" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224924" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711550" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mastocytosis complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28739366" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of Mastocytosis in Pregnancy: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27089859" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797792" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509466" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Case-control cohort study of patients' perceptions of disability in mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565772" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2040876" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A case of systemic mastocytosis; therapeutic efficacy of ketotifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14960756" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481708" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24950847" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544095" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120017" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429499" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Survey of aspirin administration in systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110198" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cromolyn sodium in the management of systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21782049" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570833" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systemic mastocytosis and bone involvement in a cohort of 75 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897317" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24954632" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Zoledronic acid in osteoporosis secondary to mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27239674" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Endocrine manifestations of systemic mastocytosis in bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787907" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787907" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Avapritinib versus placebo in indolent systemic mastocytosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29890238" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691739" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : [Interferon alpha and systemic mastocytosis. Analysis of therapeutic efficacy in 6 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34729775" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12664011" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2288395" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873577" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mastocytosis and allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177694" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19627278" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206512" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135713" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16825870" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mastocytosis and Hymenoptera venom allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31306487" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269681" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19432937" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22312942" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Unpredicted adverse reaction to omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12056960" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19541349" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363219" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25688753" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27762455" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281840" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31151985" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1750431" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23436294" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Systemic mastocytosis in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18404201" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27428296" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069279" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
